Could NUTRA PHARMA CORPORATION (OTCMKTS:NPHC) Skyrocket? The Stock Had Too Little Sellers

July 18, 2017 - By Vivian Currie

The stock of NUTRA PHARMA CORPORATION (OTCMKTS:NPHC) registered a decrease of 65.03% in short interest. NPHC’s total short interest was 26,300 shares in July as published by FINRA. Its down 65.03% from 75,200 shares, reported previously.

It closed at $0.0014 lastly. It is down 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Nutra Pharma Corp. is a biopharmaceutical company. The company has market cap of $374,724. The Firm is engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies, as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. It currently has negative earnings. The Company’s subsidiary and drug discovery arm, ReceptoPharm, Inc. , carries its homeopathic and drug discovery research and clinical development and has developed homeopathic drugs for the treatment of pain: Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe (Stage II) chronic pain; Nyloxin and Nyloxin Extra Strength, stronger versions of Cobroxin, and Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs.

More recent Nutra Pharma Corp. (OTCMKTS:NPHC) news were published by: Livetradingnews.com which released: “Nutra Pharma Corp. (OTCMKTS:NPHC) Working on HIV and Multiple Sclerosis” on September 23, 2016. Also Medgadget.com published the news titled: “Nutra Pharma Corp (NPHC) – Financial and Strategic SWOT Analysis” on July 08, 2017. Finance.Yahoo.com‘s news article titled: “Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com” with publication date: March 14, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.